Ratio of serum matrix metalloproteinases and their inhibitors in chronic insomnia patients

Cakir, Aysen; Bican Demir, Aylin; Kahveci, Nevzat

doi:10.5455/annalsmedres.2023.08.218

Ratio of serum matrix metalloproteinases and their inhibitors in chronic insomnia patients

Aysen CAKIR, (Bursa Uludağ Üniversitesi, Tıp Fakültesi, Fizyoloji Anabilim Dalı, Bursa, Türkiye)

Aylin BİCAN DEMİR, (Bursa Uludağ Üniversitesi, Tıp Fakültesi, Nöroloji Anabilim Dalı, Bursa, Türkiye)

Nevzat KAHVECİ (Bursa Uludağ Üniversitesi, Tıp Fakültesi, Fizyoloji Anabilim Dalı, Bursa, Türkiye)

Annals of Medical Research

4 0

Yıl: 2023 Cilt: 30 Sayı: 10 Sayfa Aralığı: 1271 - 1275 Metin Dili: İngilizce DOI: 10.5455/annalsmedres.2023.08.218 İndeks Tarihi: 30-10-2023

Ratio of serum matrix metalloproteinases and their inhibitors in chronic insomnia patients

Öz:

Aim: Sleep is an essential part of a healthy life. Many people experience insomnia due to their living conditions. Matrix metalloproteinases (MMPs) play an essential role in remodeling the microenvironment. Tissue inhibitors of MMPs (TIMPs) maintain a balance with MMPs. Disruption of the balance causes various pathologies. The aim of the study is to elucidate the effects of sleep disturbance on matrix metalloproteinases and inhibitors by comparing MMP-2/TIMP-2 and MMP-9/TIMP-1 ratio in the serum of patients with chronic insomnia to healthy controls. Materials and Methods: This study included 40 adult males diagnosed with chronic insomnia and 40 healthy individuals as a control group. Blood samples were obtained from the brachial vein and subsequently centrifuged at 2,000 rpm for 15 minutes to collect serum samples. MMP-2, MMP-9, TIMP-1, and TIMP-2 levels were analyzed using commercial Enzyme-linked immunosorbent assay (ELISA) kit protocols with the obtained serum samples. Results: Consequently, in this study it was demonstrated a higher MMP-2/TIMP-2 ratio in chronic insomnia patients when compared to healthy controls, whereas the MMP9/TIMP-1 ratio remained unchanged. Conclusion: These results suggest that higher MMP2/TIMP2 ratio may potentially contribute to the pathogenesis of diseases associated with sleep deprivation.

Anahtar Kelime: Matrix metalloproteinase Tissue inhibitors of MMPs Chronic insomnia

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Rasch B, Born J. About sleep’s role in memory. Physiol Rev. 2013;93(2):681–766.
2. Hirshkowitz M, Whiton K, Albert SM, et al. National Sleep Foundation’s updated sleep duration recommendations: Final report. Sleep Heal. 2015;1(4):233–43.
3. Tarokh L, Saletin JM, Carskadon MA. Sleep in adolescence: Physiology, cognition and mental health . Neuroscience and Biobehavioral Reviews. 2016;70:182–8.
4. Chattu VK, Manzar MD, Kumary S, Burman D, Spence DW, Pandi-Perumal SR. The global problem of insufficient sleep and its serious public health implications. 2019;7(1):1.
5. Noguti J, Ribeiro DA. Sleep deprivation and carcinogenesis: The role of melatonin. Sleep Sci. 2012;5(2):65–7.
6. Somarajan BI, Khanday MA, Mallick BN. Rapid eye movement sleep deprivation induces neuronal apoptosis by noradrenaline acting on alpha1 adrenoceptor and by triggering mitochondrial intrinsic pathway. Front Neurol. 2016;7:25.
7. Cakir A, Ocalan B, Koc C, et al. Effects of CDP-choline administration on learning and memory in REM sleep-deprived rats. Physiol Behav. 2020;213:112703.
8. Singh A, Kukreti R, Saso L, Kukreti S. Oxidative stress: A key modulator in neurodegenerative diseases. Molecules. 2019;24:1583.
9. Ohayon MM, Caulet M, Guilleminault C. How a general population perceives its sleep and how this relates to the complaint of insomnia. Sleep. 1997;20(9):715–23.
10. Espie CA. Revisiting the Psychobiological Inhibition Model: a conceptual framework for understanding and treating insomnia using cognitive and behavioural therapeutics (CBTx). Journal of Sleep Research. 2023; e13841.
11. Bonnet MH, Arand DL. Hyperarousal and insomnia: State of the science. Sleep Medicine Reviews. 2010;14(1): 9–15.
12. Vgontzas AN, Bixler EO, Lin HM, et al. Chronic insomnia is associated with nyctohemeral activation of the hypothalamicpituitary-adrenal axis: Clinical implications. J Clin Endocrinol Metab. 2001;86(8):3787–94.
13. Besedovsky L, Lange T, Born J. Sleep and immune function. Pflugers Archiv European Journal of Physiology. 2012;463:121– 37.
14. Cui N, Hu M, Khalil RA. Biochemical and Biological Attributes of Matrix Metalloproteinases. In: Progress in Molecular Biology and Translational Science. 2017;1–73.
15. Massova I, Kotra LP, Fridman R, Mobashery S. Matrix metalloproteinases: structures, evolution, and diversification. FASEB J. 1998;12(12):1075–95.
16. Cabral-Pacheco GA, Garza-Veloz I, Rosa CCD La, et al. The roles of matrix metalloproteinases and their inhibitors in human diseases. Int J Mol Sci. 2020;21(24):1–53.
17. Small CD, Crawford BD. Matrix metalloproteinases in neural development: A phylogenetically diverse perspective. Neural Regeneration Research. 2016;11:357–62.
18. Mukherjee A, Swarnakar S. Implication of matrix metalloproteinases in regulating neuronal disorder. Mol Biol Rep. 2015;42(1):1–11.
19. Cakir A, Ocalan Esmerce B, et al. Effects of uridine administration on hippocampal matrix metalloproteinases and their endogenous inhibitors in REM sleep-deprived rats. Brain Res. 2022;1793.
20. Tokito A, Jougasaki M. Matrix metalloproteinases in nonneoplastic disorders. International Journal of Molecular Sciences. 2016; 17:1178.
21. Brkic M, Balusu S, Libert C, Vandenbroucke RE. Friends or Foes: Matrix Metalloproteinases and Their Multifaceted Roles in Neurodegenerative Diseases. Mediators of Inflammation. 2015.
22. Avolio C, Filippi M, Tortorella C, et al. Serum MMP-9/TIMP1 and MMP-2/TIMP-2 ratios in multiple sclerosis: Relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment. Mult Scler. 2005;11(4):441–6.
23. Kanesaka T, Mori M, Hattori T, Oki T, Kuwabara S. Serum matrix metalloproteinase-3 levels correlate with disease activity in relapsin
24. Fainardi E, Castellazzi M, Tamborino C, et al. Potential relevance of cerebrospinal fluid and serum levels and intrathecal synthesis of active matrix metalloproteinase-2 (MMP-2) as markers of disease remission in patients with multiple sclerosis. Mult Scler. 2009;15(5):547–54.
25. Rempe RG, Hartz AMS, Bauer B. Matrix metalloproteinases in the brain and blood-brain barrier: Versatile breakers and makers. Journal of Cerebral Blood Flow and Metabolism. 2016; 36:1481–507.
26. Åkerstedt T, Olsson T, Alfredsson L, Hedström AK. Insufficient sleep during adolescence and risk of multiple sclerosis: Results from a Swedish case-control study. J Neurol Neurosurg Psychiatry. 2023;94(5):331–6.
27. Garcia-Montojo M, Dominguez-Mozo MI, De Las Heras V, et al. Neutralizing antibodies, MxA expression and MMP-9/TIMP-1 ratio as markers of bioavailability of interferon-beta treatment in multiple sclerosis patients: A two-year follow-up study. Eur J Neurol. 2010;17(3):470–8.
28. Sokolowska B, Jozwik A, Niebroj-Dobosz I, Janik P, Kwiecinski H. Evaluation of matrix metalloproteinases in serum of patients with amyotrophic lateral sclerosis with pattern recognition methods. J Physiol Pharmacol. 2009;60 Suppl 5:117–20.
29. Lorenzl S, Narr S, Angele B, et al. The matrix metalloproteinases inhibitor Ro 26-2853 extends survival in transgenic ALS mice. Exp Neurol. 2006;200(1):166–71.
30. Cai Q, Li M, Li Q. Sleep-based therapy: A new treatment for amyotrophic lateral sclerosis. Brain Sci Adv. 2021;7(3):155–62.
31. Tiseo C, Vacca A, Felbush A, et al. Migraine and sleep disorders: a systematic review. Journal of Headache and Pain. 2020;21:126.
32. Martins-Oliveira A, Speciali JG, Dach F, et al. Different circulating metalloproteinases profiles in women with migraine with and without aura. Clin Chim Acta. 2009;408(1–2):60–4.
33. Rosell A, Alvarez-Sabín J, Arenillas JF, et al. A matrix metalloproteinase protein array reveals a strong relation between MMP9 and MMP-13 with diffusion-weighted image lesion increase in human stroke. Stroke. 2005;36(7):1415–20.
34. Wilczynski GM, Konopacki FA, Wilczek E, et al. Important role of matrix metalloproteinase 9 in epileptogenesis. J Cell Biol. 2008;180(5):1021–35.
35. Lian X, Gu J, Wang S, et al. Effects of sleep habits on acute myocardial infarction risk and severity of coronary artery disease in Chinese population. BMC Cardiovasc Disord. 2021;21(1):481.
36. Newby AC. Metalloproteinase production from macrophages – a perfect storm leading to atherosclerotic plaque rupture and myocardial infarction. Experimental Physiology. 2016; 101:1327– 37.
37. Zucker S, Cao J, Chen WT. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene. 2000;19:6642–50.
38. Ning D, Fang Y, Zhang W. Association of habitual sleep duration and its trajectory with the risk of cancer according to sex and body mass index in a population-based cohort. Cancer. 2023;1:1–13.
39. Jezierska A, Motyl T. Matrix metalloproteinase-2 involvement in breast cancer progression: A mini-review. Medical Science Monitor. 2009; 15:32–40.
40. Sheen-Chen SM, Chen HS, Eng HL, Sheen CC, Chen WJ. Serum levels of matrix metalloproteinase 2 in patients with breast cancer. Cancer Lett. 2001;173(1):79–82.

APA	Cakir A, Bican Demir A, Kahveci N (2023). Ratio of serum matrix metalloproteinases and their inhibitors in chronic insomnia patients. , 1271 - 1275. 10.5455/annalsmedres.2023.08.218
Chicago	Cakir Aysen,Bican Demir Aylin,Kahveci Nevzat Ratio of serum matrix metalloproteinases and their inhibitors in chronic insomnia patients. (2023): 1271 - 1275. 10.5455/annalsmedres.2023.08.218
MLA	Cakir Aysen,Bican Demir Aylin,Kahveci Nevzat Ratio of serum matrix metalloproteinases and their inhibitors in chronic insomnia patients. , 2023, ss.1271 - 1275. 10.5455/annalsmedres.2023.08.218
AMA	Cakir A,Bican Demir A,Kahveci N Ratio of serum matrix metalloproteinases and their inhibitors in chronic insomnia patients. . 2023; 1271 - 1275. 10.5455/annalsmedres.2023.08.218
Vancouver	Cakir A,Bican Demir A,Kahveci N Ratio of serum matrix metalloproteinases and their inhibitors in chronic insomnia patients. . 2023; 1271 - 1275. 10.5455/annalsmedres.2023.08.218
IEEE	Cakir A,Bican Demir A,Kahveci N "Ratio of serum matrix metalloproteinases and their inhibitors in chronic insomnia patients." , ss.1271 - 1275, 2023. 10.5455/annalsmedres.2023.08.218
ISNAD	Cakir, Aysen vd. "Ratio of serum matrix metalloproteinases and their inhibitors in chronic insomnia patients". (2023), 1271-1275. https://doi.org/10.5455/annalsmedres.2023.08.218

APA	Cakir A, Bican Demir A, Kahveci N (2023). Ratio of serum matrix metalloproteinases and their inhibitors in chronic insomnia patients. Annals of Medical Research, 30(10), 1271 - 1275. 10.5455/annalsmedres.2023.08.218
Chicago	Cakir Aysen,Bican Demir Aylin,Kahveci Nevzat Ratio of serum matrix metalloproteinases and their inhibitors in chronic insomnia patients. Annals of Medical Research 30, no.10 (2023): 1271 - 1275. 10.5455/annalsmedres.2023.08.218
MLA	Cakir Aysen,Bican Demir Aylin,Kahveci Nevzat Ratio of serum matrix metalloproteinases and their inhibitors in chronic insomnia patients. Annals of Medical Research, vol.30, no.10, 2023, ss.1271 - 1275. 10.5455/annalsmedres.2023.08.218
AMA	Cakir A,Bican Demir A,Kahveci N Ratio of serum matrix metalloproteinases and their inhibitors in chronic insomnia patients. Annals of Medical Research. 2023; 30(10): 1271 - 1275. 10.5455/annalsmedres.2023.08.218
Vancouver	Cakir A,Bican Demir A,Kahveci N Ratio of serum matrix metalloproteinases and their inhibitors in chronic insomnia patients. Annals of Medical Research. 2023; 30(10): 1271 - 1275. 10.5455/annalsmedres.2023.08.218
IEEE	Cakir A,Bican Demir A,Kahveci N "Ratio of serum matrix metalloproteinases and their inhibitors in chronic insomnia patients." Annals of Medical Research, 30, ss.1271 - 1275, 2023. 10.5455/annalsmedres.2023.08.218
ISNAD	Cakir, Aysen vd. "Ratio of serum matrix metalloproteinases and their inhibitors in chronic insomnia patients". Annals of Medical Research 30/10 (2023), 1271-1275. https://doi.org/10.5455/annalsmedres.2023.08.218